Clipperton served as the exclusive financial advisor to Tilak Healthcare in a 10 million euro fundraising round led by Cap Horn and Elaia Partners, with participation from historical investors Swen Capital Partners and iBionext Growth Fund. They were joined by Laboratoires Théa, Adélie, and several renowned business angels and ophthalmologists.
A solution linking a video game and a medical device
This operation aims to accelerate the deployment of OdySight in France and internationally. OdySight is the first solution that combines a medical device and a mobile video game for remote monitoring of age-related vision disorders. It also involves developing new solutions for other medical conditions.
The arrival of the new shareholder, Théa, Europe’s leading independent ophthalmology laboratory, reinforces the value and importance of OdySight in visual health. It aligns with the collaboration between Tilak Healthcare and Théa in deploying this solution and opening new opportunities in patient care and healthcare professional support.
We are very proud to announce this fundraising and welcome new investors specializing in digital technologies and healthcare, alongside our historical partners who renew their trust. They share our ambition to revolutionize the ophthalmology care journey with the contribution of digital and video game technologies, thus helping to address challenges faced by healthcare systems worldwide.Edouard Gasser, CEO and co-founder of Tilak Healthcare
Established in 2016, Tilak is part of the iBionext ecosystem and specializes in digital health, particularly in developing a medical video game platform prescribed by healthcare professionals to support the treatment of certain chronic diseases.
The company has developed OdySight, a Class I medical device with CE marking. It is the first solution that combines a medical device and a mobile video game for remote monitoring of age-related vision disorders. Since its launch, this solution has optimized the care of 12,000 European patients suffering from retinal diseases such as AMD (Age-related Macular Degeneration) or Diabetic Retinopathy by facilitating real-time monitoring of their visual acuity.
Since its inception, Tilak Healthcare has succeeded in establishing itself in telemonitoring, interpreting health data remotely for patient medical follow-up, which is now covered in France. The company has also identified a sustainable business model that is expected to achieve profitability by 2025.
Published by the Editorial Staff on